MedTrace Logo

Vyndaqel Capsules Special Investigation (ATTR-CM)

NCT04108091 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1214

Last updated 2026-05-18

Study results available
· View outcomes & findings →

Summary

Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan. This study is conducted in accordance with the protocol even when Vynmac is used, and information the use of Vynmac during the observation period is also collected.

Conditions

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions

DRUG

Treatment for TTR amyloidosis

The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.

DRUG

Treatment for TTR amyloidosis

The usual adult dose is 61 mg of tafamidis orally once daily.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-03
Primary Completion
2025-03-27
Completion
2025-03-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04108091 on ClinicalTrials.gov